The temporal changes of amyloid beta levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment [ Time Frame: 22 hours ] [ Designated as safety issue: No ]

To compare the changes of amyloid beta levels between the baseline (9 hours) and after single dose of GSK933776 iv administration of 13 hours

Secondary Outcome Measures:

The temporal changes of total and free amyloid beta levels in plasma after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment [ Time Frame: Two months ] [ Designated as safety issue: No ]

The temporal changes of Tau and phosphor Tau - 181 levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment [ Time Frame: 22 hours ] [ Designated as safety issue: No ]

Estimated pharmacokinetic parameters of AUC, Cmax and Tmax in CSF and plasma at multiple time points with various intervals. [ Time Frame: three months ] [ Designated as safety issue: No ]

To assess the safety and tolerability after single dose of GSK933776 administration. [ Time Frame: three months ] [ Designated as safety issue: No ]

This is a phase I, an open label, single dose and parallel group study to assess short term pharmacodynamics and safety of GSK933776. The effect on the beta amyloid levels will be assessed in early (MCI) and mild Alzheimer's disease (AD) patients after a single dose of GSK933776 by i.v. administration.

Stable dose of cholinesterase inhibitors, memantine or selegine or no treatment

Body weight less than 120 kg

Willingness to comply with contraceptive methods if self or partner is of child-bearing potential

Exclusion Criteria:

Any other cause of dementia

Other significant neurologic or psychiatric illness

Hachinski Ischemia Score >4

More than 3 microbleeds on MRI

Type 2 diabetes not controlled by diet

Risk of cerebrovascular disease, cerebral haemorrhage or stroke

History of systemic autoimmune disease

Use of platelet anti-aggregates or anti-coagulants (Aspirin up to 325 mg/day is allowable)

Use of chronic corticosteroids

Uncontrolled hypertension in spite of antihypertensive medications

Renal or hepatic insufficiency or clinically significant anaemia

In nursing home care

Contraindications to lumbar puncture or MRI

Prior participation in therapeutic studies only after adequate wash-out period

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01424436